Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Immune checkpoint inhibitors (ICIs) offer new options for the treatment of patients with solid cancers worldwide. The majority of colorectal cancers (CRC) are proficient in mismatch-repair (pMMR) genes, harboring fewer tumor antigens and are insensitive to ICIs. These tumors are often found to be immune-deserted. We hypothesized that forcing immune cell infiltration into the tumor microenvironment followed by immune ignition by PD1 blockade may initiate a positive immune cycle that can boost antitumor immunity. Bioinformatics using a public database suggested that IFNγ was a key indicator of immune status and prognosis in CRC. Intratumoral administration of IFNγ increased immune cells infiltration into the tumor, but induced PD-L1 expression. A combined treatment strategy using IFNγ and anti-PD-1 antibody significantly increased T cell killing of tumor cells in vitro and showed synergistic inhibition of tumor growth in a mouse model of CRC. CyTOF found drastic changes in the immune microenvironment upon combined immunotherapy. Treatment with IFNγ and anti-PD1 antibody in CT26 tumors significantly increased infiltration of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). IFNγ had a more pronounced effect in decreasing intratumoral M2-like macrophages, while PD1 blockade increased the population of CD8+Ly6C + T cells in the tumor microenvironment, creating a more pro-inflammatory microenvironment. Additionally, PD1 induced increased expression of lymphocyte activating 3 (LAG3) in a significant fraction of CD8+ T cells and Treg cells, indicating potential drug resistance and feedback mechanisms. In conclusion, our work provides preclinical data for the Combined immunotherapy of CRC using intratumoral delivery of IFNγ and systemic anti-PD1 monoclonoal antibody.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:588 |
---|---|
Enthalten in: |
Cancer letters - 588(2024) vom: 28. Apr., Seite 216798 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tang, Yang [VerfasserIn] |
---|
Links: |
---|
Themen: |
82115-62-6 |
---|
Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.canlet.2024.216798 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369569083 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369569083 | ||
003 | DE-627 | ||
005 | 20240409232614.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240312s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.canlet.2024.216798 |2 doi | |
028 | 5 | 2 | |a pubmed24n1370.xml |
035 | |a (DE-627)NLM369569083 | ||
035 | |a (NLM)38467181 | ||
035 | |a (PII)S0304-3835(24)00191-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tang, Yang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.04.2024 | ||
500 | |a Date Revised 09.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
520 | |a Immune checkpoint inhibitors (ICIs) offer new options for the treatment of patients with solid cancers worldwide. The majority of colorectal cancers (CRC) are proficient in mismatch-repair (pMMR) genes, harboring fewer tumor antigens and are insensitive to ICIs. These tumors are often found to be immune-deserted. We hypothesized that forcing immune cell infiltration into the tumor microenvironment followed by immune ignition by PD1 blockade may initiate a positive immune cycle that can boost antitumor immunity. Bioinformatics using a public database suggested that IFNγ was a key indicator of immune status and prognosis in CRC. Intratumoral administration of IFNγ increased immune cells infiltration into the tumor, but induced PD-L1 expression. A combined treatment strategy using IFNγ and anti-PD-1 antibody significantly increased T cell killing of tumor cells in vitro and showed synergistic inhibition of tumor growth in a mouse model of CRC. CyTOF found drastic changes in the immune microenvironment upon combined immunotherapy. Treatment with IFNγ and anti-PD1 antibody in CT26 tumors significantly increased infiltration of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). IFNγ had a more pronounced effect in decreasing intratumoral M2-like macrophages, while PD1 blockade increased the population of CD8+Ly6C + T cells in the tumor microenvironment, creating a more pro-inflammatory microenvironment. Additionally, PD1 induced increased expression of lymphocyte activating 3 (LAG3) in a significant fraction of CD8+ T cells and Treg cells, indicating potential drug resistance and feedback mechanisms. In conclusion, our work provides preclinical data for the Combined immunotherapy of CRC using intratumoral delivery of IFNγ and systemic anti-PD1 monoclonoal antibody | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Colorectal cancer | |
650 | 4 | |a Combined immunotherapy | |
650 | 4 | |a Interferon gamma | |
650 | 4 | |a Programmed cell death protein 1 | |
650 | 7 | |a Interferon-gamma |2 NLM | |
650 | 7 | |a 82115-62-6 |2 NLM | |
700 | 1 | |a Wei, Jingsun |e verfasserin |4 aut | |
700 | 1 | |a Ge, Xiaoxu |e verfasserin |4 aut | |
700 | 1 | |a Yu, Chengxuan |e verfasserin |4 aut | |
700 | 1 | |a Lu, Wei |e verfasserin |4 aut | |
700 | 1 | |a Qian, Yucheng |e verfasserin |4 aut | |
700 | 1 | |a Yang, Hang |e verfasserin |4 aut | |
700 | 1 | |a Fu, Dongliang |e verfasserin |4 aut | |
700 | 1 | |a Fang, Yimin |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Xinyi |e verfasserin |4 aut | |
700 | 1 | |a Wang, Zhanhuai |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Qian |e verfasserin |4 aut | |
700 | 1 | |a Ding, Kefeng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 588(2024) vom: 28. Apr., Seite 216798 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
773 | 1 | 8 | |g volume:588 |g year:2024 |g day:28 |g month:04 |g pages:216798 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216798 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 588 |j 2024 |b 28 |c 04 |h 216798 |